Evidence map›Paper›PMID 31148473›Full record

ArticleClinical trials (London, England)2019

The Habit Formation trial of behavioral economic interventions to improve statin use and reduce the risk of cardiovascular disease: Rationale, design and methodologies.

Mary E Putt, Peter P Reese, Kevin G Volpp, Louise B Russell, George Loewenstein, Jiali Yan, David Pagnotti, Ryan McGilloway, Troyen Brennen, Darra Finnerty and 3 more

Open access · greenAbstract readClinical Trial Protocol
In one paragraph

Article in Clinical trials (London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Using Clinical Trial Data to Estimate the Costs of Behavioral Interventions for Potential Adopters: A Guide for Trialists.Medical decision making : an international journal of the Society for Medical Decision Making · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Mary E Putt1 Department of Biostatistics, Epidemiology & Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0001-7954-1288
Peter P Reese1 Department of Biostatistics, Epidemiology & Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Kevin G Volpp3 Department of Medical Ethics and Health Policy, Perelman School of Medicine, Center for Health Incentives and Behavioral Economics, University of Pennsylvania, Philadelphia, PA, USA.
Louise B Russell3 Department of Medical Ethics and Health Policy, Perelman School of Medicine, Center for Health Incentives and Behavioral Economics, University of Pennsylvania, Philadelphia, PA, USA.
George Loewenstein5 Department of Social and Decision Sciences, Carnegie Mellon University, Pittsburgh, PA, USA.
Jiali Yan3 Department of Medical Ethics and Health Policy, Perelman School of Medicine, Center for Health Incentives and Behavioral Economics, University of Pennsylvania, Philadelphia, PA, USA.
David Pagnotti3 Department of Medical Ethics and Health Policy, Perelman School of Medicine, Center for Health Incentives and Behavioral Economics, University of Pennsylvania, Philadelphia, PA, USA.
Ryan McGilloway3 Department of Medical Ethics and Health Policy, Perelman School of Medicine, Center for Health Incentives and Behavioral Economics, University of Pennsylvania, Philadelphia, PA, USA.
Troyen Brennen6 Department of Health Policy & Management, T.H. Chan School of Public Health, Harvard University, Boston, MA, USA.
Darra Finnerty3 Department of Medical Ethics and Health Policy, Perelman School of Medicine, Center for Health Incentives and Behavioral Economics, University of Pennsylvania, Philadelphia, PA, USA.
Karen Hoffer3 Department of Medical Ethics and Health Policy, Perelman School of Medicine, Center for Health Incentives and Behavioral Economics, University of Pennsylvania, Philadelphia, PA, USA.
Sakshum Chadha3 Department of Medical Ethics and Health Policy, Perelman School of Medicine, Center for Health Incentives and Behavioral Economics, University of Pennsylvania, Philadelphia, PA, USA.
Iwan Barankay7 Department of Management and Department of Business Economics and Public Policy, The Wharton School, University of Pennsylvania, Philadelphia, PA, USA.
University of Pennsylvania · USDecision Sciences (United States) · USHarvard University · USPhiladelphia VA Medical Center · US

Funding

A Randomized Controlled Trial of Incentives for Habit FormationR01AG043844 · NIA · UNIVERSITY OF PENNSYLVANIA · PI BARANKAY, IWAN, REESE, PETER PHILIP · 2012 to 2015
$2.3M
NIA NIH HHS R01 AG043844
6 · The paper itself

Abstract

backgroundLow adherence to statin (HMG-CoA reductase inhibitors) medication is common. Here, we report on the design and implementation of the Habit Formation trial. This clinical trial assessed whether the interventions, based on principles from behavioral economics, might improve statin adherence and lipid control in at-risk populations. We describe the rationale and methods for the trial, recruitment, conduct and follow-up. We also report on several barriers we encountered with recruitment and conduct of the trial, solutions we devised and efforts we will make to assess their impact on our study.

methodsHabit Formation is a four-arm randomized controlled trial. Recruitment of 805 participants at elevated risk of atherosclerotic cardiovascular disease with evidence of sub-optimal statin adherence and low-density lipoprotein (LDL) control is complete. Initially, we recruited from large employers (Employers) and a national health insurance company (Insurers) using mailed letters; individuals with a statin Medication Possession Ratio less than 80% were invited to participate. Respondents were enrolled if a laboratory measurement of low-density lipoprotein was >130 mg/dL. Subsequently, we recruited participants from the Penn Medicine Health System; individuals with usual-care low-density lipoprotein of >100 mg/dL in the electronic medical record were recruited using phone, text, email, and regular mail. Eligible participants self-reported incomplete medication adherence. During a 6-month intervention period, all participants received a wireless-enabled pill bottle for their statins and daily reminder messages to take their medication. Principles of behavioral economics were used to design three financial incentives, specifically a Simple Daily Sweepstakes rewarding daily medication adherence, a Deadline Sweepstakes where participants received either a full or reduced incentive depending on whether they took their medication before or after a daily reminder or Sweepstakes Plus Deposit Contract with incentives divided between daily sweepstakes and a monthly deposit. Six months post-incentives, we compared the primary outcome, mean change from baseline low-density lipoprotein, across arms. RESULTS AND LESSONS LEARNED: Health system recruitment yielded substantially better enrollment and was cost-efficient. Despite unexpected systematic failure and/or poor availability of two wireless pill bottles, we achieved enrollment targets and implemented the interventions. For new trials, we will routinely monitor device function and have contingency plans in the event of systemic failure.

conclusionInterventions used in the Habit Formation trial could be translated into clinical practice. Within a large health system, successful recruitment depended on identification of eligible individuals through their electronic medical record, along with flexible ways of contacting these individuals. Challenges with device failure were manageable. The study will add to our understanding of optimally structuring and implementing incentives to motivate durable behavior change.

Indexed as

Medication AdherenceMotivationAdultAgedCardiovascular DiseasesCarotid Artery DiseasesEconomics, BehavioralHumansHydroxymethylglutaryl-CoA Reductase InhibitorsLipoproteins, LDLMiddle AgedRandomized Controlled Trials as TopicReminder SystemsResearch DesignTelecommunicationsText MessagingHydroxymethylglutaryl-CoA Reductase InhibitorsLipoproteins, LDLBehavioral economicscoronary vascular diseasediabeteselectronic pill bottlefinancial incentivepragmatic trialrandomized trialstatin medication

Identifiers

PMID31148473
PMCPMC6663645
OpenAlexW2947593233

What OpenQuestion holds

Texttitle and abstract
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.